JC

Joseph Charalel

Vice President at Pivotal bioVenture Partners

Stanford, California

Overview 

Joseph Charalel is a Life Sciences investor at Pivotal bioVenture Partners in Stanford, California. He has a background in cancer research and genomics, and has held key roles as a Vice President and Senior Associate at Pivotal bioVenture Partners, as well as experience at prominent organizations like Bain & Company and Stanford University School of Medicine. Highlights of Joseph Charalel's career include his role as a General Partner at Mythos Biotechnology Fund and his current position at Pivotal bioVenture Partners, where he focuses on investing in companies in the life sciences sector, particularly in therapeutics and biotechnology, in the San Francisco Bay Area.

Work Experience 

  • Vice President

    2024 - Current

    • Lead diligence / source new investment deals • Support portfolio companies at the board level • Manage positions in public biotech portfolio companies

  • Senior Associate

    2022 - 2023

  • Board Observer

    2023

Evommune is a biotechnology company that develops therapeutics that halt progressive disease and address their symptoms.

Raised $268,000,000.00 from NEXTBio Capital, RTW Investments, Longwood Fund, RA Capital Management, Sectoral Asset Management, Marshall Wace, Avego Bioscience Capital, SymBiosis, FemHealth Ventures and Andera Partners.

  • Board Observer

    2022

Avalyn Pharma is a biopharma company developing therapies for the treatment of idiopathic pulmonary fibrosis and other respiratory diseases.

Raised $272,500,000.00 from Novo Holdings, F-Prime Capital, SR One, Norwest Venture Partners, RiverVest, Rock Springs Capital, Perceptive Advisors, Surveyor Capital, Pivotal bioVenture Partners and Vida Ventures.

  • Board Observer

    2022

Fountain Therapeutics is discovering and developing treatments for aging-associated diseases.

Raised $25,999,999.00 from Khosla Ventures, Eli Lilly & Company Foundation, R42 Group, Nan Fung Life Sciences, Alexandria Venture Investments, Khosla Ventures, Nan Fung Life Sciences and Nan Fung Life Sciences.

  • PhD Candidate in Genetics

    2013

    • Perform research in the laboratory of Dr. Christina Curtis on the genetic and epigenetic basis of drug resistance in HER2+ breast cancers via multi-omic profiling. Focus on using genome-wide sequencing assays and machine learning to understand drug response using in vitro model systems and patient data. (2015-Present) • Researcher in the laboratory of Dr. Atul Butte (now at UCSF). Worked on in silico characterization of cancer cell lines as tumor models using publicly available omics data. (2014-2015)

  • Guest Lecturer

    2023

    Guest lecturer on valuation methodology - INDE 209: Analysis of Public Companies in the Life Sciences

  • Board Observer

    2023 - 2024

Aptihealth specializes in behavioral health, health plans, primary care, therapy, direct messaging, and medication management services.

Raised $65,000,000.00 from What If Ventures, Pivotal Life Sciences, Claritas Capital, Takeda Digital Ventures, Olive Tree Ventures and Vista Credit Partners.

  • Manager

    2018 - 2021

    Focused on healthcare and investment due diligence

  • General Partner

    2017 - 2018

    • Equity partner and manager in small-cap biotech fund led by Stanford trainees

  • Intern

    2017 - 2018

    • Performed due diligence to identify potential new investment opportunities and develop comprehensive thesis for a particular therapeutic area • Contributed to company analysis efforts which led to investment decisions • Led key opinion leader calls, analyzed primary research literature, analyst reports to develop comprehensive commercial and scientific view of the key opportunities in the space • Synthesized and presented findings to Longitude leadership

Longitude Capital is a venture capital firm that invests in biotechnology and medical technology companies.

Articles About Joseph

Relevant Websites